Showing results out of
Jordi van Gestel and Maria Zimmermann-Kogadeeva each receive 1.5 million EUR funding for research projects on microbial predators and the gut microbiome respectively
EMBL ANNOUNCEMENTSLAB MATTERS2023
embl-announcementslab-matters
Researchers studying a massive cohort of European patients have found that commonly prescribed drugs for cardiometabolic disorders can have long-term effects on the gut microbiome. Such effects can complicate the understanding of how disease affects the microbiome and must be taken into…
SCIENCE & TECHNOLOGY2021
sciencescience-technology
Maria Zimmermann-Kogadeeva is one of EMBL’s newest group leaders and a computational biologist whose research group applies computational modelling to better understand the metabolism of gut bacteria and their potential to have far-reaching impacts on other organs.
LAB MATTERSPEOPLE & PERSPECTIVES2021
lab-matterspeople-perspectives
No results found